JAGX
NASDAQ · Pharmaceuticals
Jaguar Health Inc
$0.40
0.00 (-0.50%)
Financial Highlights (FY 2026)
Revenue
123.62M
Net Income
-407,090,049
Gross Margin
83.3%
Profit Margin
-329.3%
Rev Growth
+39.2%
D/E Ratio
3.64
Revenue & Net Income
Margin Trends
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Gross Margin | 83.3% | 83.3% | 61.3% | 61.3% |
| Operating Margin | -253.1% | -227.8% | 27.6% | 29.3% |
| Profit Margin | -329.3% | -312.8% | 23.6% | 22.9% |
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 123.62M | 88.82M | 728.2K | 878.3K |
| Gross Profit | 102.94M | 73.96M | 446.4K | 538.4K |
| Operating Income | -312,901,059 | -202,321,253 | 200.8K | 257.3K |
| Net Income | -407,090,049 | -263,223,682 | 171.9K | 200.8K |
| Gross Margin | 83.3% | 83.3% | 61.3% | 61.3% |
| Operating Margin | -253.1% | -227.8% | 27.6% | 29.3% |
| Profit Margin | -329.3% | -312.8% | 23.6% | 22.9% |
| Rev Growth | +39.2% | +39.2% | -5.9% | +16.6% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 614.5K | 614.5K | 719.4K | 546.9K |
| Total Equity | 168.9K | 168.9K | 1.37M | 1.50M |
| D/E Ratio | 3.64 | 3.64 | 0.52 | 0.37 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -292,266,879 | -199,478,076 | 249.9K | 289.1K |
| Free Cash Flow | — | — | 132.1K | 184.4K |